Deutsche Bank AG Has $2.55 Million Holdings in Harmony Biosciences Holdings, Inc. $HRMY

Key Points

• Deutsche Bank AG has reduced its stake in Harmony Biosciences Holdings by 10.7%, selling 9,172 shares during the first quarter, leaving it with 76,777 shares valued at approximately $2.5 million.
• Harmony Biosciences announced a missed earnings per share estimate of $0.68 for the last quarter, against analysts' expectations of $0.78, while revenue increased by 16% year over year.
• Currently, the stock has a consensus rating of "Buy" with an average target price of $51.00, following recent upgrades from firms like Cantor Fitzgerald and Mizuho.

Deutsche Bank AG reduced its stake in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 10.7% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 76,777 shares of the company's stock after selling 9,172 shares during the quarter. Deutsche Bank AG owned about 0.13% of Harmony Biosciences worth $2,548,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. GAMMA Investing LLC grew its stake in Harmony Biosciences by 222.9% during the 1st quarter. GAMMA Investing LLC now owns 2,929 shares of the company's stock worth $97,000 after buying an additional 2,022 shares during the last quarter. Allspring Global Investments Holdings LLC grew its stake in Harmony Biosciences by 52.0% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 20,221 shares of the company's stock worth $671,000 after buying an additional 6,915 shares during the last quarter. Arizona State Retirement System grew its stake in Harmony Biosciences by 6.4% during the 1st quarter. Arizona State Retirement System now owns 12,261 shares of the company's stock worth $407,000 after buying an additional 737 shares during the last quarter. Two Sigma Advisers LP grew its stake in Harmony Biosciences by 21.8% during the 4th quarter. Two Sigma Advisers LP now owns 98,900 shares of the company's stock worth $3,403,000 after buying an additional 17,700 shares during the last quarter. Finally, SG Americas Securities LLC grew its stake in Harmony Biosciences by 56.0% during the 1st quarter. SG Americas Securities LLC now owns 35,097 shares of the company's stock worth $1,165,000 after buying an additional 12,599 shares during the last quarter. 86.23% of the stock is currently owned by institutional investors.

Harmony Biosciences Price Performance

Shares of HRMY traded down $0.3650 during midday trading on Monday, reaching $37.4950. The stock had a trading volume of 43,395 shares, compared to its average volume of 650,713. Harmony Biosciences Holdings, Inc. has a 52 week low of $26.47 and a 52 week high of $41.61. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.84 and a quick ratio of 3.80. The firm's 50 day moving average price is $34.47 and its 200-day moving average price is $33.62. The company has a market capitalization of $2.16 billion, a P/E ratio of 12.17, a P/E/G ratio of 0.44 and a beta of 0.84.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $0.68 EPS for the quarter, missing analysts' consensus estimates of $0.78 by ($0.10). Harmony Biosciences had a return on equity of 26.34% and a net margin of 23.44%.The firm had revenue of $200.49 million during the quarter, compared to the consensus estimate of $204.37 million. During the same period in the prior year, the firm posted $1.05 EPS. The firm's quarterly revenue was up 16.0% on a year-over-year basis. Harmony Biosciences has set its FY 2025 guidance at EPS. On average, analysts forecast that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. Oppenheimer assumed coverage on Harmony Biosciences in a research note on Monday, June 2nd. They set an "outperform" rating and a $61.00 price objective for the company. Deutsche Bank Aktiengesellschaft reaffirmed a "buy" rating and set a $55.00 target price (up previously from $54.00) on shares of Harmony Biosciences in a research note on Thursday, July 10th. Cantor Fitzgerald upgraded Harmony Biosciences to a "strong-buy" rating in a research report on Tuesday, May 13th. Mizuho boosted their price target on Harmony Biosciences from $44.00 to $48.00 and gave the stock an "outperform" rating in a research report on Thursday, May 15th. Finally, Truist Financial began coverage on Harmony Biosciences in a research report on Monday, July 21st. They set a "buy" rating and a $48.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat.com, Harmony Biosciences presently has a consensus rating of "Buy" and an average price target of $51.00.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.